Table 2.

Randomized trials investigating adjuvant chemotherapy and/or radiotherapy in endometrial cancer

Trial (ref)	No. patients eligibility/stage	Randomization	Pelvic recurrence	Overall survival
Susumu et al. [23]	385 Stage I–III with >50% MI (60% stage IB)	Pelvic RT vs chemotherapy (3× CAP)	7% vs 7% P = ns	85% vs 87% P = ns
Maggi et al. [24]	345 IB–II grade 3 (35%) III (65%)	Pelvic RT vs chemotherapy (5× CAP)	12% vs 16% P = ns	69% vs 66% P = ns
Randall et al. [25]	396 III; IV (28%) (residual <2 cm)	WART vs chemotherapy (8× AP)	13% vs 18%	42% vs 53% P < 0.01
Morrow et al. [28]	181 Clinical stage I II (occult) 31% node+	Pelvic RT vs pelvic RT and chemotherapy (6–8× A)	N/A	No difference P = ns
Kuoppala et al. [29]	156 Stage IA g3, IB, Stage II–IIIA (46% stage IB)	Pelvic RT vs pelvic RT and chemotherapy (3× CEP)	3% vs 2% P = ns	85% vs 82% DSS 5 years P = ns
Hogberg et al. [30••]	382 Stage I–III Stage I serous (49% stage IB)	Pelvic RT vs pelvic RT and chemotherapy (4× AP/TAP/TC/TEP)	N/A	76% vs 83% P = ns
Ongoing trials	Planned no.	Randomization	Accrual January 2011
PORTEC-3	670 Stages I–III with high-risk factors; serous/cc	Pelvic RT vs RT-CT (2× C during RT and 4× TC)	300
GOG#249	562 Stages I–II with high-risk factors or serous/cc	Pelvic RT vs VBT and CT (3× TC)	175
GOG#258	804 Stages III/IV	RT-CT (2× C during RT and 4× TC) vs CT (6× TC)	132

A doxorubicin; AP doxorubicin/cisplatin; CAP cyclophosphamide/doxorubicin/cisplatin; CEP cyclophosphamide/epirubicin/cisplatin; CT chemotherapy; ns not statistically significant; RT radiation therapy; TAP paclitaxel/doxorubicin/cisplatin; TC paclitaxel/carboplatin; TEP paclitaxel/epirubicin/cisplatin; WART whole abdominal radiotherapy